Abstract Background Molecular signatures that predict outcome in tamoxifen treated breast cancer patients have been identified. For the first time, we compared these response profiles in an independent cohort of (neo)adjuvant systemic treatment naïve breast cancer patients treated with first-line tamoxifen for metastatic disease. Methods From a consecutive series of 246 estrogen receptor (ER) positive primary tumors, gene expression profiling was performed on available frozen tumors using 44K oligoarrays (n = 69). A 78-gene tamoxifen response profile (formerly consisting of 81 cDNA-clones), a 21-gene set (microarraybased Recurrence Score), as well as the HOXB13-IL17BR ratio (Two-Gene-Index, RT-PCR) were analyzed. Performance of signatures in relation to time to progression (TTP) was compared with standard immunohistochemical (IHC) markers: ER, progesterone receptor (PgR) and HER2. Results In univariate analyses, the 78-gene tamoxifen response profile, 21-gene set and HOXB13-IL17BR ratio were all significantly associated with TTP with hazard ratios of 2.2 (95% CI 1.3-3.7, P = 0.005), 2.3 (95% CI 1.3-4.0, P = 0.003) and 4.2 (95% CI 1.4-12.3, P = 0.009), respectively. The concordance among the three classifiers was relatively low, they classified only 45-61% of patients in the same category. In multivariate analyses, the association remained significant for the 78-gene profile and the 21-gene set after adjusting for ER and PgR. Conclusion The 78-gene tamoxifen response profile, the 21-gene set and the HOXB13-IL17BR ratio were all significantly associated with TTP in an independent patient series treated with tamoxifen. The addition of multigene assays to ER (IHC) improves the prediction of outcome in tamoxifen treated patients and deserves incorporation in future clinical studies.
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Introduction
Adjuvant tamoxifen treatment reduces the risk of breast cancer death by 31% in patients with ER-positive disease [1] . However, a substantial proportion of patients develops metastases despite tamoxifen treatment. Moreover, only half of the recurrences in ER-positive breast tumors responds to tamoxifen while the other half is resistant [2] . Although aromatase inhibitors do prolong disease-free survival compared to tamoxifen [3] , tamoxifen still has a major role in breast cancer treatment [4] . In addition, a survival benefit has been shown for sequential tamoxifen and an aromatase inhibitor [5, 6] . A molecular test helping clinicians to make a choice between starting with either tamoxifen, an aromatase inhibitor or rather with chemotherapy would have enormous potential for tailoring treatment.
Molecular signatures that correlate with outcome of breast cancer patients who received adjuvant tamoxifen treatment, have been identified, namely a 21-gene set (Recurrence Score) and a HOXB13-IL17BR ratio [7, 8] . A disadvantage of assessing response in the adjuvant setting is that both response of tumor cells to tamoxifen as well as intrinsic aggressiveness of the malignancy are measured. Furthermore, some resistant tumors will not recur because they were already cured by surgery and radiation. The proportion of this group of patients is unknown. In contrast, studies in the metastatic disease setting provide information on decrease of tumor load after treatment and thereby on sensitivity to a specific drug.
Even in cases where the interval between primary tumor and metastasis is long, gene profiles are maintained in metastatic lesions [9] . In this view, an 81-gene signature using primary tumors of patients treated with tamoxifen for metastatic disease was developed [10] . Using this signature, patients who had a short TTP could be identified. This study showed the relevance of profiling of the primary tumor for response prediction in the metastatic disease setting.
Ultimately, guided decisions for adjuvant treatment are still most crucial and could result in significant survival benefit. However, therapy response can only be defined in patients with measurable disease. Therefore, validation of predictive markers in the metastatic disease setting is desirable before tests are applied to the adjuvant treatment setting.
To provide a robust estimate of the likelihood of response to tamoxifen predicted by the 81-gene profile, 21-gene set and HOXB13-IL17BR ratio, we compared these profiles in an independent cohort of (neo)adjuvant systemic treatment naïve breast cancer patients treated with first-line tamoxifen for metastatic disease.
Methods

Patients
A consecutive series of 246 patients (diagnosed 1984-1997) was selected from the medical registry of the Netherlands Cancer Institute according to following criteria: (1) invasive breast carcinomas, (2) relapse of disease before 2002, for which first-line tamoxifen had been given, (3) no adjuvant systemic treatment, (4) patients had received tamoxifen for at least 4 weeks, which is an adequate period to allow judgment of therapeutic effect.
Patients who had bilateral cancer or had developed either contra lateral or a second primary breast tumor were excluded (n = 35). After reviewing medical charts, 10 patients who had received surgery or radiation for all metastatic lesions were excluded. In addition, 21 patients were excluded because no follow-up was available. After pathology revision, 22 patients with an ER-negative tumor were excluded. Of the remaining 158 patients, for 77 patients frozen tumors were available. Finally, 8 patients were excluded either due to lack of tumor cells in frozen material or no good quality RNA could be extracted. The analyses presented here are based on 69 patients. According to routine practice, patients attended the hospital every 4-8 weeks and were restaged (by imaging, physical examination and biochemical markers) if indicated based on presented symptoms. During tamoxifen treatment, eight women had undergone ovarian ablation. Besides bisphosphanates, no systemic treatment had been prescribed. This study received approval of the Ethical Committee.
Gene expression profiling RNA isolation was performed as described previously [11] . RNA amplification, labeling and hybridization to a 44K oligoarray (Agilent Technologies) was performed as described previously [12] . Intensities were normalized using Feature Extraction software version 7.5.
78-gene tamoxifen response profile
Training (data online in Supplements)
Since the 81-gene profile [10] had been discovered using 19K cDNA arrays, we re-hybridized the original training set (n = 46, Erasmus MC) on the more advanced 44K oligoarray platform. For 40 tumors (22 non-responders, 18 responders) out of this training set, sufficient RNA was available. To allow comparison of the training with the validation set (Netherlands Cancer Institute) described in this paper, a median centering was applied to the genes separately for each hospital. After this correction, log-ratios were in the same range in the training and validation set.
We mapped, based on Genbank accessions and Unigene identifiers (version 2005), 78 of the 81 genes to the 44K oligoarray. These 78 genes were represented by 161 oligos. A univariate t-test (BRB Array Tools, version 3.4.0) was used to select the oligo per gene that was most differentially expressed among classes. The 78 oligos are listed online in the Supplements. Hereafter the 81-gene profile is referred to as '78-gene profile'.
In the previous study [10] , an algorithm comparable to the compound covariate predictor had been used. Using the oligoarray data, this algorithm left 10% unclassified. To overcome this problem, a slightly different algorithm was used: the nearest centroid classifier [11, 13, 14] . A template was created containing the mean expression of the nonresponders. For all tumors the Pearson correlation with this template was calculated. To minimize the risk of misclassifying tumors with a non-responder profile, the threshold was set at a correlation of 0.0750 which resulted in a smaller than 10% false negative rate. Results of the training set are available online in the Supplements.
Validation (data presented in paper)
For each tumor, a Pearson correlation with the 'nonresponder' template of the training set was calculated. When the correlation was more than 0.0750, a patient was assigned to the non-responder profile group.
21-gene set (Recurrence Score)
To classify tumors using the Recurrence Score, we used microarray data for all 21 genes (mapped to 44K array based on Genbank and Unigene identifiers) and applied the algorithm described by Paik et al. [7] . Briefly, expression of 16 target genes was normalized relative to 5 reference genes. If genes were represented by more probes, values were averaged. Next, data were transformed from log-10 to log-2 and target genes were scaled as described by Paik et al. [7] . Using cut-offs described in Paik et al., we assigned patients into the Low, Intermediate or High Risk group, respectively.
HOXB13-IL17BR ratio
The HOXB13-IL17BR ratio was generated using RT-PCR as described by Jansen et al. [15] . The cut-off of 2.99 for tamoxifen treatment in metastatic disease setting previously defined by Jansen et al. was used [15] .
Immunohistochemistry (IHC)
Biopsies of 600-lm were taken from each paraffinembedded tumor and arrayed in triplicate in a new paraffin block (tissue microarray). IHC for ER-alpha and HER2 and additional chromogenic in situ hybridization for HER2, was performed and scored as described previously [16, 17] . The primary antibody directed against PgR (R-1, Klinipath, Duiven, Netherlands) was diluted 1:500. Staining for ER and PgR was interpreted as positive when more than 10% of tumor cells were stained [18, 19] .
Statistics
Disease-Free Interval (DFI) was measured using interval between primary surgery and start of first-line tamoxifen treatment for relapse of disease. TTP was considered the primary outcome measured as time in months after start of tamoxifen until treatment was ended because of progression. Survival curves were generated using the KaplanMeier method. For analysis regarding TTP, P-values from log-rank tests were used. Since only 10% (n = 7) of the patients were at risk after 3 years of tamoxifen, patients with TTP exceeding 36 months were censored. Cox proportional-hazards analysis was used to calculate hazard ratios (HR). For multivariate analyses, three models were used. Menopausal status (pre vs. post), DFI (B2 vs.
[2 years), grade (I/II vs. III) and HER2 (3+ vs. rest) were considered as possible confounders and added to the models, that tested ER, PgR and each of the profiles. Since only patients who developed a relapse were included, the distribution of DFI between classes predicted by the profiles were compared by the Mann-Whitney U-or KruskalWallis-test. Analyses were performed using SPSS 14.0.1.
Results
Gene expression profiles of primary tumors of 69 adjuvant systemic treatment naïve breast cancer patients who PROGNOSIS ( Fig.2D-E developed a relapse of disease for which they were treated with first-line tamoxifen, were related to TTP while on tamoxifen. The study design is illustrated in Fig. 1 . Clinical features are summarized in Table 1 . The 78-gene tamoxifen response profile (microarray), the 21-gene set (microarray-based Recurrence Score) and the HOXB13-IL17BR ratio (RT-PCR) predicted 55% (n = 38), 59% (n = 41) and 7% (n = 4) respectively, of the patients as having a 'non-response' or 'High Risk' expression profile (Table 1) .
Survival analysis (TTP)
Figure 2a-c shows the Kaplan-Meier curves for the profiles in relation to TTP. For the 78-gene profile, the difference in median TTP for the predicted groups was 14 months (7 vs. 21) (log-rank P = 0.004). The High-, Intermediate-and Low Risk group as determined by the 21-gene set showed a median TTP of 10, 21 and 28 months, respectively (log-rank P = 0.003). The two groups defined by HOXB13-IL17BR differed by 10 months (3 vs. 13, log-rank 0.004).
In univariate Cox regression analysis (Table 2) , patients classified as non-responder by the 78-gene profile had a HR of 2.16 (95% CI = 1.27-3.67, P = 0.005) compared to tumors predicted as responder.
Patients classified as High Risk by the 21 genes had worse outcome while on tamoxifen compared to patients classified as Low or Intermediate Risk (HR = 2.31, 95% CI = 1.32-4.02, P = 0.003). The HR for HOXB13-IL17BR was 4.20 (95% CI = 1.43-12.29, P = 0.009). The traditional markers ER, PgR and HER2 were also significantly associated with TTP.
Sensitivity and specificity of 78-gene tamoxifen response profile, 21-gene set and HOXB13-IL17BR ratio Next, we evaluated the predictive capacity of the 78-gene profile, 21-gene set, HOXB13-IL17BR ratio, ER (low vs. high) and PgR (negative vs. positive) ( Table 3) . Patients who had a TTP of less than 6 months were considered as non-responders. The 78-gene profile and 21-gene set reached high accuracy for identifying non-responding tumors with a sensitivity of 84.2 (95% CI 60.4-96.6) and 73.7 (95% CI 53.9-93.5), respectively. On the contrary, the HOXB13-IL17BR ratio as well as the ER identified responding tumors with high specificity: 95.2% (95% CI 83.8-99.4) and 79.6% (95% CI 68.3-90.9), respectively. 
Concordance of profiles
Next, we compared the predictors using two-way contingency tables (see online Supplements). Comparison of classification according to the 78-gene profile with classification according to the 21-gene set and the HOXB13-IL17BR ratio revealed a relatively low number of concordant cases of 42 (61%) and 30 (50%), respectively. Twenty-seven patients (45%) were classified in the same category by the 21-gene set and the HOXB13-IL17BR ratio.
Multivariate Cox regression analysis (TTP)
To assess whether gene expression profiles could potentially add predictive information to the routinely used ER and PgR, three different multivariate analyses were performed. 
Association of profiles with disease-free interval
To investigate whether the 78-gene profile, 21-gene set and HOXB13-IL17BR ratio are actually predicting progression after tamoxifen rather than reporting prognosis, the association with DFI was studied. No adjuvant systemic treatment was administered in this interval. For details of study design see Fig. 1 . Figure 2d -f shows the KaplanMeier curves for the three gene profiles in relation to DFI. The 78-gene profile was not significantly related to the DFI. In contrast, the 21-gene set (P = 0.002) and the HOXB13-IL17BR ratio (P = 0.038) did predict DFI.
Discussion
A profile of 81 genes had recently been identified in breast cancer as being associated with resistance to tamoxifen in the metastatic disease setting [10] . Other investigators had described a 21-gene set (Recurrence Score) and a HOXB13-IL17BR ratio for the prediction of outcome following tamoxifen treatment in the adjuvant setting [7, 8] .
Simultaneous analysis of these gene profiles by applying them to a single dataset is necessary for direct comparison of the classifiers. For the first time, we have assessed the performance of these three profiles in an independent cohort of adjuvant systemic treatment naïve breast cancer patients treated with first-line tamoxifen for relapse of disease. The 78-gene profile (78 oligos representing the formerly used 81 cDNA clones), the 21-gene set (microarray-based Recurrence Score) as well as the HOXB13-IL17BR ratio (RT-PCR) were significantly associated with TTP of patients treated with first-line tamoxifen. In multivariate analyses only the 78-gene profile as well as the 21-gene set remained significantly associated with TTP independent of ER and PgR and other traditional factors. Nowadays, the majority of patients with ER-positive breast cancer receives endocrine treatment in the adjuvant setting. A drawback of assessing tamoxifen response in the adjuvant setting is that both response of tumor cells to tamoxifen (drug response prediction) as well as intrinsic aggressiveness (prognosis) of the malignancy are measured. The best way to unravel this prognostic and predictive effect is analyzing the performance of a predictor in a randomized trial including an untreated control group. So far, for none of the classifiers studied in our series this has been published with regard to tamoxifen. Currently, almost no physician will withhold endocrine treatment from a patient with ER-positive disease, so for the untreated control group researchers depend on trials performed in the past. Unfortunately, during the years that those trials were carried out, most hospitals did not freeze tumors. Although RNA extraction from FFPE material is possible [7, 8] , to our knowledge there are no whole genome datasets available including patients who were treated in a randomized trial to compare the prognostic and predictive value of a tamoxifen response profile.
An alternative approach is to study tamoxifen response in patients who did not receive any adjuvant systemic Abbreviations: no., number of patients; yrs, years; CI, confidence interval; ER, estrogen receptor; IHC, immunohistochemistry; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2 a At diagnosis of primary tumor therapy and subsequently developed a relapse of their disease for which tamoxifen was prescribed. The TTP while on tamoxifen provides information on decrease or increase of tumor load and thereby to a large extent on sensitivity to tamoxifen. In contrast, the DFI in the period after primary surgery where no drugs were prescribed reflects general aggressiveness of the tumor. However, analysis of our series regarding the prognostic value of the classifiers has to be interpreted carefully. Our series was selected for having developed a relapse, i.e., patients who did not have a relapse of their disease were left out. Since a large proportion of these patients probably would have had a Low Risk profile, the data on prognosis presented here can be considered conservative estimates. In our series, the 78-gene profile, the 21-gene set as well as the HOXB13-IL17BR ratio were predictive for TTP while on tamoxifen. With regard to the DFI, the HOXB13-IL17BR ratio and the 21-gene set were associated with time to relapse while the 78-gene profile was not. Our data suggest that the 78-gene profile is primarily a predictive marker. Regarding the 21-gene set, previous studies showed that the Recurrence Score captures both prognosis and tamoxifen response [7, 20, 21] . Our study confirms this mixed effect. Although the HOXB13-IL17BR ratio was significantly associated with TTP, after adjustment for other predictive markers, the association was no longer significant. Even though Jansen et al. showed a significant relation of the HOXB13-IL17BR ratio with TTP [15] , our data suggest that this Two-Gene-Index might be somewhat more prognostic rather than predictive for tamoxifen response. This strong prognostic value is in line with previous studies [15, 22, 23] .
Since the HOXB13-IL17BR ratio was analyzed using a predefined cut-off [15] that classified only a minority of the patients as High Risk, the association with TTP in our multivariate model was less robust probably due to analyses of small subgroups. When other previously described cut-points [8, 22, 23] were applied, no stronger predictive results were obtained (data not shown).
The expression of the 21 genes was determined using array data, rather than the validated laboratory test (Oncotype DX, Genomic Health Inc.). Although this may result in an underestimation of the capacity of the 21-gene set, previous work suggests that applying the 21 genes to a microarray dataset results in accurate prediction of subgroups of patients [24, 25] .
In contrast to a previous study comparing prognostic gene profiles where high concordance among classifiers was observed [24] , profiles predicting outcome after tamoxifen treatment did not show high agreement in their classification. They classified only 45-61% of patients in the same category. The 78-gene profile and 21-gene set had relatively high sensitivity to identify non-responding tumors, while the HOXB13-IL17BR ratio identified responding tumors with a high specificity. These remarkable differences in sensitivity and specificity for the predictors suggest that if these tests will reach clinical application, the gene sets might be helpful in addressing different clinical questions. For example, does the profile identify tamoxifen responsive tumors with high accuracy or rather select the true resistant tumors? Recently, the update of the Intergroup Exemestane Study [6] suggests that postmenopausal, ER-positive breast cancer patients who switch to an aromatase inhibitor after 2-3 years on adjuvant tamoxifen will have an improvement in overall survival. The ATAC-trial showed that 5 years of adjuvant anastrozole was superior to tamoxifen in terms of diseasefree survival [3] . At this time, it is unclear whether postmenopausal patients should be treated according to the switch strategy [6] , or should start with an aromatase inhibitor upfront [3] . It is unknown whether the multigene assays predict endocrine responsiveness in general or are specific for tamoxifen resistance. Further studies have been initiated to investigate the predictive value of the 78 and 21 genes for response to aromatase inhibitors.
In conclusion, we have demonstrated that the 78-gene tamoxifen response profile as well as the 21-gene set and the HOXB13-IL17BR ratio were significantly associated with TTP in an independent patient series. The addition of multigene assays to ER improves the prediction of outcome in tamoxifen treated patients and deserves incorporation in future clinical studies. 
